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Previous studies have shown that sulfinpyrazone (one of the pyrazole group 
of compounds) prolongs platelet survival in man  and  rabbits  (1, 2, 3).  This 
could mean that some aspects of platelet function and metabolism are altered 
or that the mechanisms removing platelets from the circulation are changed. 
One of the characteristics of platelets is their response to surface stimuli  (4) 
such  as  collagen  (5, 6, 7),  antigen-antibody  complexes  (8, 9),  and  gamma 
globulln-coated surfaces (10, 11). When such a surface is presented to platelets 
they adhere to it  1 and may release  a number of substances including  adenine 
nucleotides (AMP, ADP, and ATP) (12), serotonin (13), and a factor or factors 
which increase vessel permeability (14). The released ADP is believed to cause 
platelet  aggregation  (12).  Platelets may also phagocytose particulate matter 
(9, 15-17).  In may be the participation of the platelets in these reactions which 
influences their survival in the circulation.  If the action of the pyrazole drugs in 
prolonging platelet survival is primarily on the platelets' response to surface 
stimuli,  then it would be anticipated that the platelets from animals or subjects 
given these drugs would show an  altered  response.  We have,  therefore,  ex- 
amined  the  effect of  the  pyrazole compounds on some of the factors which 
induce platelet aggregation. 
Materials  and  Methods 
Pyrazole Compounds (18).--Sulfinpyrazone (Anturan,  Gcigy Pharmaceuticals, Montreal, 
Quebec) 10% solution  G-28315-P,2206  was  used in  the  in  vivo  experiments  and snlfinpyrazone 
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powder 18057 (solubilized  in water with NaOH in equimolar amounts) in the in vitro experi- 
ments. 
Sulfinpyrazone placebo: the solvent in which the 10% solution of Anturan was prepared. 
Phenylbutazone  (Butazolidin,  Geigy  Pharmaceuticals)  20%  solution  G-13871,  5670454 
was  used  in  the in vivo experiments  and  phenylbutazone  powder  G-15137  (solubilized  in 
water with NaOH in equimolar amounts) in the in vitro experiments. 
Butazolidin placebo: the solvent in which the 20% solution of Butazolidin was prepared. 
Tyrode's Solutions.-- 
Tyrode's solution was prepared  as described by Parker  (19).  Modified Tyrode's solution 
was 8 g NaC1, 0.2 g KC1, 1 g NaHCO3 0.05 g NaH2PO4.H20 and  1 g  glucose per liter, pH 
adjusted to 7.35 with NaOH. (This solution does not contain calcium or magnesium.) 
Tyrode-aibumin:  modified Tyrode's solution plus  1.4 g  bovine serum albumin  per liter 
(Calbiochem, Los Angeles,  Calif., fraction V). 
Tyrode-albumin-EDTA: 5 parts Tyrode-albumin plus 1 part EDTA-saline solution (2% 
disodium ethylenediaminetetraacetate, 0.33% NaC1). 
Tyrode-gelatin solution: Tyrode's solution plus 2.5 g gelatin per liter. 
Adenine Nudeotides.--ATP,  ADP, and AMP (Sigma Chemical Co., St. Louis, Mo.)  were 
dissolved in Tyrode's solution to the required concentrations. 
Thrombin.--Crude bovine thrombin  (Parke,  Davis  & Co., Detroit, Mich.) was dissolved 
in Tyrode's solution to the desired concentrations, usually 5 NIH units per milliliter. 
Gamma Globulin.--The  crude gamma globulin fraction  (16%)  (Connaught  Medical Re- 
search Laboratories, Toronto, Ontario) was dialyzed against two changes (each of 4000 ml) of 
Tyrode's solution at 4°C for 12 hr, diluted with Tyrode's solution to 1.6%, and centrifuged at 
110,000 g for 30 min to remove any insoluble material. 
Collagen Suspension.--2  g  of commercial collagen (Sigma Chemical Co.)  were suspended 
in 100 mi of Tyrode's solution and blended in a Waring Blendor for a total of 5 rain (avoiding 
heating). The mixture was centrifuged at 810 g for 15 rain to remove coarse particulate matter. 
The supernatant  suspension  was  diluted  with Tyrode's solution  to  a  concentration  which 
would still produce maximum aggregation of the platelets being tested, but on further dilution 
would give less than maximum aggregation. 
Immune  Complexes.--Antigen-antibody complexes were prepared  as previously described 
(9).  The concentration used  to induce platelet  aggregation was  adjusted  by dilution with 
Tyrode's solution, as described for the collagen suspension. 
Latex Coated with Gamma Globulin.--A  30%  polystyrene latex suspension  (British Drug 
Houses,  Toronto,  Ontario)  was  diluted  to 0.1%  with  Tyrode's solution.  1 part  was  then 
added to 9 parts of a gamma globulin solution (prepared as described above) and allowed to 
stand at room temperature for 15 rain.  The coated latex particles were recovered by centrif- 
ugation  at 40,000  g for 20 rain at 4°C and washed twice with Tyrode's solution. They were 
finally resuspended in Tyrode's solution at a concentration of 0.1%. The concentration used 
to induce platelet aggregation was adjusted by dilution with Tyrode's solution, as described 
for the collagen suspension. 
Animals.--Pigs  and  rabbits  were anesthetized with sodium pentabarbitol  (1  gr/2.5  kg) 
for cannulation of a carotid artery and for the examination of hemostatic plug formation in 
the mesentery of the rabbits. 
Glassware.--Glassware which was to contain platelets was coated with silicone  (General 
Electric dry film SC 87 in carbon tetrachloride). 
Platelet-Rich Plasma (PRP).--Blood was taken through a carotid artery cannula into 3.8% 
trisodium citrate (1-9 parts of blood) and centrifuged at 77 g for 15 min at room temperature. 
The supernatant  PRP was removed with siliconed Pasteur  pipettes.  In some experiments, 
citrated human blood was taken from a vein in the forearm using an 18 gauge needle and a 
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Pleader Suspensions.--Blood  was  taken  from pigs into  2%  EDTA-saline  (1-9  parts  of 
blood)  either through  a  carotid  artery caunula or by collection in a  polyethylene pail at a 
slaughterhouse  (Canada Packers, Ltd., Toronto, Ontario). PRP was prepared either by  cen- 
trifuging (as described above) or by allowing the blood to stand for 2 hr at room temperature. 
The PRP was centrifuged at 650 g for 15 rain at 4°C.  The platelets were gently resuspended 
and washed twice with cold Tyrode-albumin-EDTA, recovered each time by centrifugation, 
and  finally resuspended  in Tyrode-gelatin solution to a  platelet  concentration of  500,000- 
600,000 per mm  a. The plateiet suspension was stored in an ice-water bath. 
Pla~det counts were done on a  Coulter counter as previously described  (10). 
Platda aggrega*ion was studied by the turbidimetric method previously described  (20). 
Rdease of AMP and ADP.--1 ml of plateiet suspension was mixed with 0.1 ml of a solution 
of the pyrazole drug being studied (diluted to the desired concentration with Tyrode's solu- 
tion). In the control experiments, 0.1  ml of Tyrode's solution replaced the solution of the 
pyrazole drug. In order to induce platelet aggregation and release plateiet constituents, 0.1 ml 
of a suspension of either collagen, antigen-antibody complexes,  gamma giobulin-coated latex, 
or a thrombin solution was added and the mixture was continuously shaken or stirred for 10 
rain at 37°C. Then 0.2  ml of 2% EDTA-safine was added to prevent conversion of ADP to 
AMP, and AMP to adenosine.  (The EDTA does not interfere with the analysis of ADP and 
AMP.) The suspension was chilled and centrifuged at 2000 g for 10 rain at 4°C. For AMP and 
ADP analysis,  the supernatant  was removed and  mixed with an equal volume of cold 6°/0 
perchloric acid. The precipitate was removed by centrifugation and the supernatant analyzed 
for ADP and AMP by the Boehringer test kit method as described by Adam  (21) and by 
Glyun et al. (10). For AMP and ADP analysis, the plateiet button was resuspended in 0.25 M 
sucrose (equal in volume to the final platelet suspension).  1 ml of this suspension was mixed 
with 1 ml of cold 6% perchlorie and the assay continued as described above for the superna- 
tant.  (Phenylbutazone at a final concentration of 50 ~g/ml did not affect this assay.) 
Serotonin-14C Labding of Pla~dets.--The method of labeling in vivo (10) has been described. 
The labeled compound used was 5-hydroxytryptamine-3'-14C creatinine sulphate supplied by 
the Radiochemical Centre,  Amersham, Buckinghamshire,  England.  Each rabbit  was given 
3.5 ml containing 10 ~c (350 #g). 
Rdeo~e of SerotoninJ4C from Plogdas.---Citrated platelet-rich plasma or plateiet suspen- 
sions were prepared  from the blood of  rabbits  given serotonin-14C. The release of  platelet 
constituents  and  the separation  into platelet button  and  supernatant  were carried  out  as 
described  above. In experiments in which the AMP and  ADP concentrations were deter- 
mined,  samples of the supematants  were removed for counting before the addition of per- 
chioric acid. The platelet buttons were washed three times with Tyrode-albumin-EDTA be- 
fore addition of Hyamine and transfer to counting vials. Radioactivity was determined in a 
liquid scintiUation counter as previously described (10). 
Hemostasis.--The  technique  for  evaluation  of  hemostasis  by  cutting  small  mesenteric 
vessels will be described elsewhere (22). The length of time from the onset of bleeding to its 
arrest was recorded by direct observation of the tmnsected vessels. The vessels were observed 
for 30 rain in order to note any renewed bleeding. 
Pladet survival studies on rabbits (3) were carried out by a modification (23) of the method 
of  Leeksma  and  Cohen  (24) using  diisopropyl  phosphorofluoridate-=P  (sterile  solution) 
(DFP-=P) obtained from the Radiochemical Centre. The specific activity of the labeled DFP 
at the time of its shipment was between 200 and 240/~c/mg of DFP. It was used for platelet 
survival studies up to 3 wk after shipment.  The dose of labeled DFP ranged from 0.03  to 
0.12 mg/kg body weight. The rabbits were bled from ear veins with siliconized syringes con- 
taining 2% EDTA-saline (1-9 parts of blood). With the exception of three animals, matched 
pairs  of phenylbutazone-treated  and  nontreated  rabbits  were  used.  The  phenylbutazone- 174  PLATELET RESPONSE AND  PYRAZOLE  COMPOUNDS 
treated animals received 100 mg of phenylbutazone  (0.5 mi of 20% solution)  twice  daily, 
intramuscularly,  for 3 days before, and also during,  the platelet  survival  study. The non- 
treated animals received the same volume of the Butazolidin placebo solution. The platelet 
half-life value for each animal was calculated by the method of least squares. Platelet  turn- 
over was calculated as 
0.693 X  average number of platelets  per mms 
half-life in days 
This must not be interpreted  as meanlng that we believe that plateiets  disappear  from the 
circulation in an exponential manner. We have used this as a means of providing an objective 
index of platelet  survival (1). 
Assay of phenylbutazone and sulflnpyrasone in plasma was carried out as described by Bums 
et al.  (25, 26). (Extraction  of plasma from untreated animals gave a variable  blank  value 
between 1 and 5 mg per 100 ml of plasma.) 
Specimens for electron microscopy were immediately added to cold 1% osmium tetroxide in 
Tyrode solution (pH 7.4). After 1.5-2 hr in the osmic acid solution, the tissue was dehydrated 
in increasing concentrations  of ethanol,  and treated  in propylene  oxide for 0.5-1  hr. The 
specimen was then placed in a mixture of equal parts of Epon 812 and propylene oxide, for 
8-12 hr, and then embedded in Epon 812.0.5 # thick sections were cut on a  Porter-Blum 
microtome and stained with azure H for orientation by light microscopy. A suitable area was 
selected and ultrathin sections cut and stained with lead hydroxide or with lead  hydroxide 
and uranyl acetate. The sections were picked up on uncoated grids and examined in either a 
Philips 200 or RCA EMU-3F electron microscope. 
RESULTS 
In Vitro Studies.--It was found that when sulfinpyrazone, or phenylbutazone, 
was  added  to  citrated  platelet-rich  plasma,  platelet  aggregation  induced  by 
collagen  was  suppressed.  However,  platelet  aggregation induced  by ADP  or 
thrombin was not affected. The results of experiments with phenylbutazone and 
sulfinpyrazone are shown in Text-figs.  1 a and 1 b. Inhibition of platelet aggre- 
gation by the pyrazole compounds was found with pig, rabbit, or human PRP. 
Text-fig.  2  shows the  effect of different concentrations of phenylbutazone on 
platelet aggregation induced by collagen. 
To examine the influence of these drugs in a  system free of plasma proteins 
and  also  one  in which  the  effect  of antigen-antibody  complexes  and  gamma 
globulin-coated surfaces can easily be explored, we studied the action of these 
compounds in a  suspension of washed platelets.  It was found that sulfinpyra- 
zone  and  phenylbutazone  inhibited  the  action of  collagen,  antigen-antibody 
complexes,  and gamma globulin-coated latex in inducing platelet  aggregation 
in a washed platelet suspension (Text-fig. 3). The action of thrombin, however, 
was not inhibited. We could not examine ADP in this system because most of 
our washed platelet suspensions do not aggregate when ADP is added. 
Collagen, antigen-antibody complexes,  and gamma globulin-coated surfaces 
are known to cause the release of platelet constituents such as serotonin, ADP, 
and AMP. We therefore examined the effect of the pyrazole compounds on the 
release  of  nucleofides  from  the  platelets.  It was  found  that  when  phenyl- PACKHAM~  WARRIOR~  GLYNN~  SENYI~  AND  MUSTARD  175 
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T~xT-FIo. 2.  Suppression  of platelet aggregation in a  suspension  of pig platelets by in- 
creasing  concentrations  of phenylbutazone.  No  phenylbuta~ne  was  added  to  the  upper 
sample. The fin1 concentrations of phenylbutazone in the other samples are shown with the 
corresponding curves. 
butazone  or  sulfinpyrazone was  added  to  a  platelet  suspension  in  a  final 
concentration of 100/~g/ml, the drugs diminished the amount of nucleotides in 
the form of ADP and AMP released into the ambient fluid (Table I). In Table PACKHAM~ WARRIOR~ GLYNN~ SENYI, AND MUSTARD  177 
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T~xT-Fm. 3. Platelet aggregation in a suspension of washed pig platelets, showing sup- 
pression by phenylbutazone of the effect of collagen, antigen-antibody complex, and gamma 
globulin-coated latex part.ides. 
II it can be seen that, coincident with the inhibition of release of nucleotides 
into the ambient fluid, the platelet levels of these nucleotides were higher and 
the effect was proportional to the amount of pyrazole compound added to the 
suspension. In Table III the inhibition of the release of AMP and ADP in the 
presence of different concentrations of sulfinpyrazone is shown to be related to 
the  degree  of  suppression  of  aggregation  which  occurred  in  the  platelet 
suspension.  It was  also found, in other experiments, that  the fall in platelet 
ATP usually induced by the stimuli  was  diminished by the presence of the 
pyrazole compounds.  Platelets labeled in vivo with 5-hydroxytryptamine-l~C 
showed less release of radioactivity into the ambient fluid in the presence of the 
pyrazole drugs when stimulated with collagen, antigen-antibody complexes, or 
gamma globulin-coated latex (Table IV). 178  PLATELET  R.ESPONSE AND  PYRAZOLE COMPOLrNDS 
TABLE  I 
Effect o/Pyrazole Drugs on Surface-Induced AMP and A DP rdease  from Plalelets 
Stimulus* 
Collagen 
Collagen 
Collagen 
Collagen 
Gamma globulin-coated latex 
Gamma globulin-coated latex 
Antigen-antibody complex 
Antigen-antibody complex 
+ 
+ 
+ 
÷ 
Solution added to 
platelet suspension 
AMP and ADP in ambient  fluid 
after release  reaction 
(nanomoles/ml  platelet 
suspension) 
AMP + 
ADP 
62.6 
48.7 
68.9 
41.7 
25.7 
19.2 
31.3 
19.4 
71.0 
59.1 
94.3 
64.3 
94.3 
80.4 
59.2 
36.2 
47.0 
30.9 
65.1 
42.1 
45.3 
26.1 
51.5 
28.5 
57.1 
36.5 
* The results between the horizontal lines are from experiments carried out on the same 
day. 
:~ These results have not been corrected for possible AMP contamination of the NADH 
used in the enzyme assay. In addition, the control platelet suspension usually showed some 
release of AMP and ADP into the ambient fluid and this has not been subtracted from the 
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TABLE II 
Effect of Pyrazole Drugs on AMP and ADP Levds in Platdets Following Reaction with Collagen 
Final concentration of  AMP  and ADP remaining in platelet button after 
pyrazole compound in  release reaction (nanomoles/ml platelet 
Stimulus  platelct suspension  suspension) 
Phenylbutazone  Sulfinpyrazone  AMP*  ADP  AMP +  ADP 
#g/rat 
Collagen 
Collagen 
~c 
pg/ml 
0 
1 
10 
100 
0 
1 
10 
100 
32.5  60.6 
60.9  76.6 
68.6  77.9 
69.9  93.3 
51.5  53.6 
52.2  71.7 
66.8  70.9 
64.7  74.5 
93.1 
137.5 
146.5 
163.2 
105.1 
123.9 
137.7 
139.2 
* It must not be concluded that this represents the AMP level of fresh platelets.  See note 
under Table I. 
T,~BLE  III 
Relationship  Between the Degree of Inhibition of AMP and ADP Release and Suppression  of 
Platda Aggregation 
Final concentration of 
sulfmpyrazone.in platelet 
suspension 
#g/~ 
0 
0.01 
0.1 
1.0 
10 
100 
AMP and ADP in ambient fluid following release 
reaction* (nanomoles/ml of platelet suspension) 
AMPt 
36.2 
37.9 
33.1 
31.3 
24.0 
20.8 
ADP 
32.7 
32.7 
30.6 
25.7 
20.9 
20.9 
Suppression of 
aggregation 
(% of control)§ 
0 
1 
26 
30 
92 
92 
* Aggregation was produced by a collagen suspension. 
See note under Table I. 
§ Maximum vertical deflection on  the tracing during aggregation was assigned a value of 
100% for the control sample (no snlfinpyrazone). The maximum deflections obtained in the 
presence of sulfinpyrazone were calculated as percentages of this and subtracted from 100% 
to give "suppression of aggregation." These values are dependent on the collagen concentra- 
tion and  represent relative values on]y with a  given collagen suspension. 
In  contrast  to  the  effect  of  the  pyrazole  drugs  on  the  release  of 
platelet constituents  induced by particulate  stimuli,  there was no inhibition of 
thrombin-induced  release of serotoninJ~C, AMP,  or ADP  from platelets (Table 
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TABLE IV 
Effect  of Phenylbutazone  on  Serotonin-14C  Release from  Platdets  by  a  Collagen  Suspension 
Platelets 
in 
1 mlof 
CitratedPRP 
L*  tc 
tg  c~ 
ct  Ct 
Suspension 
cl 
cc 
Tyrode's 
solution 
ml 
0.2 
0.1 
0.2 
0.1 
0.1 ml of 
Phenylbutazone 
solution 
m 
1 mg/ml 
100 #g/ml 
10 #g/ml 
1 mg/ml 
100 ,ug/ml 
10 #g/ml 
Collagen 
suspension 
ml 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
0.1 
Supernatant  i 
radioactivity 
cpm/O.1 ml 
192 
3,110 
1,920 
2,854 
3,548 
206 
2,907 
593 
1,460 
2,838 
Platelet 
button 
radioactivity. 
epm/S X  10  8 
platelets 
48,504 
8,772 
26,620 
17,000 
9,352 
117,392 
86,011 
111,158 
69,321 
56,027 
TABLE V 
Effect  of Phenylbutazone  on  the Release  of Serotonin-14C, ADP, and  AMP from  Platelets  by 
Thrombin 
/olume of 
platelet 
Luspenslon 
ml 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Tyrode's 
solution 
ml 
0.2 
0.1 
0.1 
0.1 
0.1 
0.I 
0.1 ml of 
Phenylbutazone 
solution 
m 
1 mg/ml 
1 mg/ml 
1 mg/ml 
100 #g/ml 
10o #g/m1 
100 #g/ml 
1 rag/ml 
100 ~g/ml 
Thrombin solution 
(Uuits/ml) 
50  5  1 
ml  ml 
).1 
0.1 
).1 
0.1 
).1 
0.1 
i 
~u  rPerd~ant 
activity 
ml  cpm/O.1  ml 
--  166 
--  3,003 
--  2,949 
0.1  3,162 
--  2,976 
--  3,040 
0.1  3,064 
--  2,999 
--  3,008 
0.1  3,045 
--  106 
--  138 
AMP and ADP in 
ambient  fluid after 
release reaction 
(Nanomoles/ml of 
platelet  suspension) 
ADP  AMP 
2.78  2.78 
13.90  11.10 
12.51  11.45 
9.73  8.33 
11.12  9.37 
12.51  8.33 
7.65  8.33 
14.60  8.68 
15.29  6.25 
7.65  7.98 
1.39  3.47 
2.09  1.74 
In  Vivo Studies.--Three  aspects of the in vivo effects of these drugs were also 
studied: the suppression of the aggregating action of collagen on platelets iso- 
lated following intravenous infusions; the effect  of  intravenous  infusions on 
hemostatic plug formation; and the effect of the drugs on platelet survival. PACKttAM~ WARRIOR~ GLYNN~ SENYI~ AND MUSTARD  181 
1.  The effect  of in vivo  administration  of pyragole drugs:Platelet  aggregation 
in citrated PRP taken from rabbits before and after infusion of 25 mg/kg of 
phenylbutazone showed a  pattern similar to that in the in vitro experiments. 
The response of the platelets in citrated platelet-rich plasma to collagen, but 
not to ADP or thrombin, was suppressed after the infusion, compared with the 
TABLE VI 
Effect of t~henytbutazene Infu,  cion~ into Rabbits on Plasma l_,~ds of Plt~ylbutazone and Ptatdtt 
Aggregation to Collagen 
Amount~o.~phenylbutazone  Phenylbutazone  per 100 ml plasma  Suppression of .auregation* 
refused  (20 rain after infusion)  (% of preinfusmn sample) 
0 
5 
5 
12.5 
25 
25 
25 
50 
50 
75 
100 
100 
100 
150 
Placebo* 
12~ 
15~ 
15~ 
mg 
1.10 
3.30 
2.27 
8.93 
5.90 
11.0 
14.9 
18.8 
21.6 
32.5 
59.2 
41.6 
30.6 
41.1 
3.7 
5.34§ 
8.2 
8.8§ 
0 
64 
100 
100 
100 
64 
91 
42 
100 
87 
93 
100 
100 
100 
0 
69§ 
51 
31§ 
See notes under Table III. 
* 6 repeated studies with the placebo solution showed no suppression of aggregation. 
l~gs. 
§ 60 rain values. 
preinfusion response. Table VI summarizes the results of infusions of various 
amounts of phenylbutazone into rabbits and pigs, and Table VII gives the re- 
suits of infusions of sulfinpyrazone into rabbits. The plasma levels of the drugs 
are tabulated,  as well as an indication of the amount of aggregation occurring 
in response to collagen. The extent of aggregation was dependent on the con- 
centration of the collagen suspension used and, because the effect of the pyrazole 
drugs could be overcome by using an excess of collagen, a suitable dilution of the 
collagen suspension had  to be  determined  empirically for the platelets  being 
tested  in  any one series  of experiments.  (Because only two or  three  animals 182  PLATELET  RESPONSE  AND  PYRAZOL]E  COMPOUNDS 
could be studied on one day, and because it was not possible to have a collagen 
suspension which would give uniform results from day to day, the variability in 
the aggregation results is to be expected.) Infusion of the pyrazole compounds 
had no detectable effect on the platelet count. Suppression of the aggregating 
effect of collagen was somewhat dependent on the plasma level of the drug. 
2. Effect on hemostatic plug formation:  Phenylbutazone was administered in- 
travenously to rabbits at a dosage which the previous experiments had indicated 
would cause a  consistent and marked suppression of collagen induced aggre- 
gation. Fig.  1 shows a motion-picture frame sequence of the normal arrest of 
bleeding from  a  transected  mesenteric vessel.  Vessels  were  transected  both 
before and after phenylbutazone infusions (or infusion of the placebo solution). 
TABLE VII 
Effect of Sulfinpyrazone In/usions into  Rabbits on Plasma Levds of Sulfinpyrazone and Platdet 
Aggregabion to Collagen 
Sulfinpyrazone  per I00  ml plasma  Suppression of aggregation* 
Sulflnpyrazone  infused  (60  rain  after  infusion)  (% of preinfusion  sample) 
mg/kg 
0 
25 
5O 
75 
100 
150 
mg 
4.5 
3.5 
21.1 
27.0 
33.1 
39.5 
0 
0 
36 
49 
69 
88 
* See note under Table III. 
It can be seen that after transection of the mesenteric vessels there was a 
gradual accumulation of material at the ends of the cut vessels. Detailed study 
of the  structure of this material  showed  that it was  primarily composed of 
platelets (Fig. 2) and that there was a marked alteration in the morphology of 
the platelets in contact with collagen at the end of the transected vessel. Even 
as the plug was forming, blood could be seen streaming through parts of it 
(Fig.  1).  Finally, the plug became sufficiently solid to arrest bleeding. In the 
rabbits  given no  treatment or infused with  the placebo material,  there was 
sometimes renewed bleeding through the plug but this usually lasted for less 
than 2 rain. The rabbits infused with phenylbutazone showed a  considerable 
lengthening in the time for the initial arrest of bleeding, and in some instances 
there was no arrest during the 30 min period of observation. When an initial 
arrest of bleeding did occur, there was frequently rebleeding through the plug, 
usually lasting 4 rain or more. In some instances, rebleeding was continuous 
throughout the observation period. Table VIII summarizes the data from these 
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3. Effect on platelet survival:  Platelet survival studies were done with rabbits 
receiving intramuscular injections  of 100 mg  of phenylbutazone twice  daily 
for 3 days before and also during the survival measurements.  The platelets were 
labeled with DFP-a*P in vivo. At daily intervals for 7 days, the platelets were 
isolated and their radioactivity  determined. The results for two pairs are shown 
in Text-Fig. 4. Table IX gives the mean results for 12 phenylbutazone-treated 
rabbits and 12 control rabbits given the placebo  solution  and illustrates that 
platelet survival (estimated as the half-life) was significantly  prolonged by this 
drug.  There was no effect on the platelet count but platelet turnover was sig- 
nificandy reduced. 
TABLE  VIII 
The Effea o] Phenylbutazone  on Hemostasis  in Transeaed Rabbit  Mesenteriz  Vessds 
Material 
infused 
None 
Placebo 
Phenylbutazone (200 
nag) 
No. of 
rabbits* 
tested 
11 
13 
9 
Total No. 
of vessels 
ol~erved~ 
64 
74 
36 
Initial bleeding  time 
Mean 
209 
215 
470§ 
SE 
$~ 
17.7 
20.1 
87,Oll 
Frequency of renewed bleeding 
None 
No.  % 
34  53 
40  54 
7  19 
Once  Twice  or 
more 
No.  1%  No.  % 
20  31  10  16 
161  22  18  24 
5  14  24  67 
I  ! 
* Rabbits were all about 2 kg in weight. 
Vessels transected were 150-200/l in diameter. 
§ 4  of the 36 vessels bled continuously during the 30 rain of observation and these are 
included in the group of 24 vessels listed as showing renewed bleeding two or more times. 
][ Significance of the difference between the mean initial bleeding time after phenylbuta- 
zone infusion and the mean initial bleeding time after placebo infusion, P  <  0.001. 
DISCUSSION 
These studies  show that platelet aggregation  induced by collagen, antigen- 
antibody complexes, or  gamma globulin-coated latex  (polystyrene) can  be 
blocked by phenylbutazone and sulfinpyrazone. The mechanism  does not ap- 
pear to be a direct inhibition of the action of ADP because ADP can cause 
aggregation  in the presence of these pyrazole drugs.  They may interfere with 
the adherence of platelets to surfaces or with reactions which occur at the plate- 
let membrane. 
The evidence from the present studies indicates that in a platelet suspension 
the pyrazole drugs diminish the amount of ADP released from the platelets by 
surface stimuli. It is assumed on the basis of the available evidence (12,13)  that 
collagen,  antigen-antibody complexes,  and  gamma globulin-coated surfaces 
induce aggregation  through the release of platelet ADP.  However,  it is also 184  PLATELET RESPONSE  AND  PYRAZOLE  COMPOUNDS 
known  s (as was the case with the suspensions in these experiments) that washed 
platelets in suspension do not usually aggregate upon the addition of ADP. It 
would seem,  therefore, in the case of the platelet suspension,  that the surface 
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TExT-FIG. 4.  The effect of phenylbutazone on platelet survival as estimated with labeled 
DFP  in rabbits. To establish a standard origin for all the curves, the radioactivity values  (as 
cpm/mg platelets) have been expressed as a percentage of the initial value. - ...........  , phenyl- 
butazone administered;  , placebo solution administered. 
stimuli, if they are inducing platelet aggregation  through the release of ADP, 
must  also  be  making  available  another  factor  involved  in  aggregation.  This 
could occur through the release of such a factor from the platelets or by alter- 
ation of the surface characteristics of the platelets.  Possibly,  the pyrazole drugs 
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exert their inhibiting effect by influencing this aspect of platelet aggregation. 
It seems most reasonable, however, that the primary action was in inhibiting 
the release of nucleofides, particularly ADP. It was found in the present experi- 
ments  that  the  degree of inhibition of  aggregation  was  proportional  to  the 
inhibition of nucleotide release.  Furthermore,  the  evidence from the  studies 
with citrated PRP indicates that ADP-induced platelet aggregation is not in- 
hibited by the pyrazole drugs, thus supporting the suggestion that inhibition of 
ADP release by surface stimuli is the most likely mechanism. 
The observation that the pyrazole drugs inhibit the release of serotonin-14C 
from  platelets  stimulated  with  collagen suggests  that  the  drugs  exert  their 
effect by diminishing the interaction of platelets with surface stimuli. 
TABLE IX 
The  l(ffect  of Phenylbutazone  on  Platelet Survival  and  Turnover  in  Rabbits 
No. of 
Treatment  obser- 
vations 
Phenylbutazone  12 
Placebo  12 
Significance of difference  be- 
tween means 
Platelet count  Platelet half-life*  Platelet turnover:~ 
No./mm3  No./mm~  days  I  days 
565,000  145,000  4.03  I  2.05  121,500  62,200 
525,0001122,000  1.7810.39  226,500  119,000 
t  =  0.74  t  =  3.73  t  =  2.70 
P  < 0.5  P  <  0.001  P  < 0.02 
* Calculated by the method of least squares. 
:~ Number/mm  3 per day. 
One of the factors in platelet aggregation induced by thrombin is the release 
of AI)P  (27).  In  these  studies,  thrombin-induced aggregation  (both  in  PRP 
and in suspension) was not inhibited by the pyrazole drugs. This indicates that 
the mechanisms involved in platelet aggregation induced by thrombin may be, 
at least in the initial stages, different from those concerned in platelet aggre- 
gation induced by the surface stimuli. 
The results from the in vivo experiments substantiate those from the in vitro 
studies.  The plasma  concentrations of the  pyrazole drugs which produce in- 
hibition of aggregation were of the same order of magnitude as those producing 
inhibition in the in vitro studies. The greatest inhibition occurred with the high- 
est plasma concentrations. 
The effect of the inhibition of platelet aggregation (induced by surface stim- 
uli) on platelet function in vivo could be important in a  number of biological 
processes. It could influence the effect of antigen-antibody complexes on plate- 
lets, and possibly the effect of microorganisms such as bacteria and viruses. In 
addition, it seems likely that it would affect processes in which collagen is an 
important stimulus in the formation of the platelet mass. It is thought that in 186  PLATELET  RESPONSE  AND  PYRAZOLE  COMPOUNDS 
the formation of a hemostatic plug at the end of a transected vessel, the stimulus 
provided by the exposed connective tissue is one of the necessary factors (13, 22, 
28,  footnote  1).  In  the  present  experiments,  the  infusion  of  high  doses  of 
phenylbutazone caused a clearly demonstrable change in the arrest of bleeding 
from the transected vessels in the mesentery of rabbits. This change consisted 
mainly of a delay in the primary arrest of bleeding and an increased suscepti- 
bility of the hemostatic plug to breakdown, with rebleeding. Because we did not 
find in any of these experiments that platelet aggregation induced by thrombin 
or ADP  was  inhibited by these pyrazole drugs,  nor were we  able  to  show in 
other studies  (2)  an  effect on blood coagulation, it is likely that  the phenyl- 
butazone influences hemostasis by inhibition of collagen-induced platelet aggre- 
gation. In studies of hemostasis in dogs with congenital defects in coagulation,  2 
we found that abnormalities in factor VIII or IX caused a  similar  pattern of 
deficient hemostasis. In factor IX-deficient dogs, the administration of phen~l- 
butazone produced a further aggravation of the hemorrhagic disorder. All this 
evidence strongly suggests that both the surface stimulus of exposed connective 
tissue  (collagen)  and blood coagulation are important in  the production of a 
stable hemostatic plug. 
We have previously shown (1,  2)  that sulfinpyrazonc administration in ade- 
quate doses prclongs platelet survival in man and rabbits. In the present study 
also,  phenylbutazone was  found to prolong platelet  survival in  rabbits.  It is 
likely that the action of the pyrazole drugs on platelet survival is related to the 
platelets' response to surface stimuli. It seems that platelet surviva], as well as 
being controlled by the age of the platelet, may also be affected by the functions 
of the platelet. 
SUMMARY 
Sulfinpyrazone and phenylbutazone block the aggregating action of collagen, 
antigen-antibody  complexes,  and  gamma  globulin-coated  surfaces  on  blood 
platelets. These drugs do not block the action of ADP or thrombin. Inhibition 
of surface-induced aggregation appears to be the result of a decreased response 
of the platelets to surface stimuli, giving rise to diminished release of platelet 
constituents,  such  as ADP  and  serotonin.  The intravenous infusion of these 
drugs produced results similar to those found in the in vitro experiments. Ad- 
ministration  of phenylbutazone in  doses  sufficient  to  produce  marked  sup- 
pression of the platelet-collagen reaction impaired hemostatic plug fornlation at 
the ends of transected mesenteric vessels in rabbits.  Since platelet function is 
considered a  factor influencing platelet survival,  the effect of phenylbutazone 
on platelet survival was examined. It was found that phenvlbutazone prolonged 
platelet survival to more than twice the normal time and reduced platelet turn- 
over by nearly 50%.  These studies  show  that  drugs  which  suppress  platelet 
response to surface stimuli alter platelet function in vivo. PACKIIAM~ WARRIOR~ GLYNN~ SENYI~ AND MUSTARD  187 
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EXPLANATION OF PLATES 
PLATE  7 
FIG.  la-c.  This  is a  motion-picture frame  sequence  of  bleeding from  transected 
vessels [arteriole (A), venule  (V)I in  the mesentery of a  rabbit.  Fig.  1 a  shows  the 
early formation of  platelet plugs  (PL)  at  the  ends  of  the  cut vessels (1  rain  after 
transection).  Fig.  1  b  shows  the  extensive platelet plug formation  around  the  cut 
vessels with arrest of bleeding from the vessels on the left side of the picture (2 rain). 
In Fig. 1 c, taken at 3 min, bleeding from the right hand vessel is not yet arrested.  × 
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(Packham et al,: Platelet response and pyrazole compounds) PLATE 8 
FIO. 2.  An electron micrograph of a platelet plug at the end of a transected mesen- 
teric blood vessel. The platelets (arrows)  in contact with the exposed  collagen (COL) 
of  the vessel  wall appear swollen,  have lost much of  their internal structure, have 
breaks in their membranes, and are less electron-dense than the platelets (PLT) which 
are remote from the collagen.  These platelets are adherent to each other but have 
retained most of their granules (GR). A red blood cell  (RBC)  is apparent near the 
upper right hand corner of the picture. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 126  PLATE  8 
(Packham et al.: Platelet response and pyrazole compounds) 